Literature DB >> 15880407

Surveyor Nuclease: a new strategy for a rapid identification of heteroplasmic mitochondrial DNA mutations in patients with respiratory chain defects.

Sylvie Bannwarth1, Vincent Procaccio, Veronique Paquis-Flucklinger.   

Abstract

Molecular analysis of mitochondrial DNA (mtDNA) is a critical step in diagnosis and genetic counseling of respiratory chain defects. No fast method is currently available for the identification of unknown mtDNA point mutations. We have developed a new strategy based on complete mtDNA PCR amplification followed by digestion with a mismatch-specific DNA endonuclease, Surveyor Nuclease. This enzyme, a member of the CEL nuclease family of plant DNA endonucleases, cleaves double-strand DNA at any mismatch site including base substitutions and small insertions/deletions. After digestion, cleavage products are separated and analyzed by agarose gel electrophoresis. The size of the digestion products indicates the location of the mutation, which is then confirmed and characterized by sequencing. Although this method allows the analysis of 2 kb mtDNA amplicons and the detection of multiple mutations within the same fragment, it does not lead to the identification of homoplasmic base substitutions. Homoplasmic pathogenic mutations have been described. Nevertheless, most homoplasmic base substitutions are neutral polymorphisms while deleterious mutations are typically heteroplasmic. Here, we report that this method can be used to detect mtDNA mutations such as m.3243A>G tRNA(Leu) and m.14709T>C tRNA(Glu) even when they are present at levels as low as 3% in DNA samples derived from patients with respiratory chain defects. Then, we tested five patients suffering from a mitochondrial respiratory chain defect and we identified a variant (m.16189T>C) in two of them, which was previously associated with susceptibility to diabetes and cardiomyopathy. In conclusion, this method can be effectively used to rapidly and completely screen the entire human mitochondrial genome for heteroplasmic mutations and in this context represents an important advance for the diagnosis of mitochondrial diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880407     DOI: 10.1002/humu.20177

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  33 in total

1.  Development of a rapid, reliable genetic test for pseudoxanthoma elasticum.

Authors:  Yanggu Shi; Sharon F Terry; Patrick F Terry; Lionel G Bercovitch; Gary F Gerard
Journal:  J Mol Diagn       Date:  2007-02       Impact factor: 5.568

2.  Screening human genes for small alterations performing an enzymatic cleavage mismatched analysis (ECMA) protocol.

Authors:  Nikolaos Vogiatzakis; Kyriaki Kekou; Christalena Sophocleous; Sophia Kitsiou; Ariadni Mavrou; Chrisa Bakoula; Emmanouel Kanavakis
Journal:  Mol Biotechnol       Date:  2007-08-03       Impact factor: 2.695

3.  Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model.

Authors:  Paula M Keeney; Caitlin K Quigley; Lisa D Dunham; Christina M Papageorge; Shilpa Iyer; Ravindar R Thomas; Kathleen M Schwarz; Patricia A Trimmer; Shaharyar M Khan; Francisco R Portell; Kristen E Bergquist; James P Bennett
Journal:  Hum Gene Ther       Date:  2009-08       Impact factor: 5.695

4.  Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy.

Authors:  David Azria; Mahmut Ozsahin; Andrew Kramar; Sheila Peters; David P Atencio; Nigel E A Crompton; Françoise Mornex; André Pèlegrin; Jean-Bernard Dubois; René-Olivier Mirimanoff; Barry S Rosenstein
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

5.  Inactivation of Pif1 helicase causes a mitochondrial myopathy in mice.

Authors:  Sylvie Bannwarth; Laetitia Berg-Alonso; Gaëlle Augé; Konstantina Fragaki; Jill E Kolesar; Françoise Lespinasse; Sandra Lacas-Gervais; Fanny Burel-Vandenbos; Elodie Villa; Frances Belmonte; Jean-François Michiels; Jean-Ehrland Ricci; Romain Gherardi; Lea Harrington; Brett A Kaufman; Véronique Paquis-Flucklinger
Journal:  Mitochondrion       Date:  2016-02-24       Impact factor: 4.160

6.  Refractory epilepsy and mitochondrial dysfunction due to GM3 synthase deficiency.

Authors:  Konstantina Fragaki; Samira Ait-El-Mkadem; Annabelle Chaussenot; Catherine Gire; Raymond Mengual; Laurent Bonesso; Marie Bénéteau; Jean-Ehrland Ricci; Valérie Desquiret-Dumas; Vincent Procaccio; Agnès Rötig; Véronique Paquis-Flucklinger
Journal:  Eur J Hum Genet       Date:  2012-09-19       Impact factor: 4.246

7.  MITOMASTER: a bioinformatics tool for the analysis of mitochondrial DNA sequences.

Authors:  Marty C Brandon; Eduardo Ruiz-Pesini; Dan Mishmar; Vincent Procaccio; Marie T Lott; Kevin Cuong Nguyen; Syawal Spolim; Upen Patil; Pierre Baldi; Douglas C Wallace
Journal:  Hum Mutat       Date:  2009-01       Impact factor: 4.878

Review 8.  The cybrid model of sporadic Parkinson's disease.

Authors:  Patricia A Trimmer; James P Bennett
Journal:  Exp Neurol       Date:  2009-03-26       Impact factor: 5.330

9.  Parkinson's disease brain mitochondria have impaired respirasome assembly, age-related increases in distribution of oxidative damage to mtDNA and no differences in heteroplasmic mtDNA mutation abundance.

Authors:  Charles R Arthur; Stephanie L Morton; Lisa D Dunham; Paula M Keeney; James P Bennett
Journal:  Mol Neurodegener       Date:  2009-09-23       Impact factor: 14.195

10.  Mutations in p53, p53 protein overexpression and breast cancer survival.

Authors:  Pavel Rossner; Marilie D Gammon; Yu-Jing Zhang; Mary Beth Terry; Hanina Hibshoosh; Lorenzo Memeo; Mahesh Mansukhani; Chang-Min Long; Gail Garbowski; Meenakshi Agrawal; Tara S Kalra; Mia M Gaudet; Susan L Teitelbaum; Alfred I Neugut; Regina M Santella
Journal:  J Cell Mol Med       Date:  2008-10-16       Impact factor: 5.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.